Varicella Vaccine: The American Experience
Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-tomoderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV)...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1992-08, Vol.166 (Supplement-1), p.S63-S68 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S68 |
|---|---|
| container_issue | Supplement-1 |
| container_start_page | S63 |
| container_title | The Journal of infectious diseases |
| container_volume | 166 |
| creator | Gershon, Anne A. LaRussa, Philip Hardy, lain Steinberg, Sharon Silverstein, Saul |
| description | Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-tomoderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV) have developed. Adult vaccinees have a lower degree of protection (70%) than children. Vaccinees who develop breakthrough varicella usually have a modified infection. Another significant advantage of vaccination is that in leukemic children it leads to a lower incidence of zoster than after natural chickenpox. It is possible to differentiate between vaccine-type and wild-type VZV using a combination of polymerase chain reaction and restriction endonuclease digestion. A new assay for antibodies to VZV measured by latex agglutination reveals that 8–10 years after vaccination antibodies are detectable in >90% of leukemic children who have not had breakthrough varicella. |
| doi_str_mv | 10.1093/infdis/166.Supplement_1.S63 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_73053091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30111789</jstor_id><sourcerecordid>30111789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-d4baab40228d61ccd764d62e17ff353d1e69fac127c358134a956b9c87ce02813</originalsourceid><addsrcrecordid>eNpNkNtKw0AQQBdRaq1-ghAQfBDS7mST3USfSqlWrBdoreLLstlMMLW5mE2g_r2pKa1PM8yZG4eQC6B9oAEbJFkcJWYAnPdndVGsMMWsktCfcXZAuuAxYXMO7JB0KXUcG_wgOCYnxiwppS7jokM6wBzKPadLrhaqTDSuVspaKK2TDK-t-SdawxSbusqs8bpoMsw0npKjWK0Mnm1jj7zejuejiT19vrsfDae2ZoJXduSGSoVuc9mPOGgdCe5G3EEQccw8FgHyIFYaHKGZ5wNzVeDxMNC-0EidptAjl-3eosy_azSVTBPz92KGeW2kYNRjNNg03rSNusyNKTGWRZmkqvyRQOXGlGxNycaU_G9KNqaa6fPtmTpMMdrPtmr2fGmqvNxhRgFA-EHD7ZYnpsL1jqvyS3LBhCcn7x_y7Yk_vjw4vlywX7voglQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73053091</pqid></control><display><type>article</type><title>Varicella Vaccine: The American Experience</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><creator>Gershon, Anne A. ; LaRussa, Philip ; Hardy, lain ; Steinberg, Sharon ; Silverstein, Saul</creator><creatorcontrib>Gershon, Anne A. ; LaRussa, Philip ; Hardy, lain ; Steinberg, Sharon ; Silverstein, Saul</creatorcontrib><description>Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-tomoderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV) have developed. Adult vaccinees have a lower degree of protection (70%) than children. Vaccinees who develop breakthrough varicella usually have a modified infection. Another significant advantage of vaccination is that in leukemic children it leads to a lower incidence of zoster than after natural chickenpox. It is possible to differentiate between vaccine-type and wild-type VZV using a combination of polymerase chain reaction and restriction endonuclease digestion. A new assay for antibodies to VZV measured by latex agglutination reveals that 8–10 years after vaccination antibodies are detectable in >90% of leukemic children who have not had breakthrough varicella.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/166.Supplement_1.S63</identifier><identifier>PMID: 1320652</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Adult ; Antibodies ; Antibodies, Viral - biosynthesis ; Chickenpox ; Chickenpox - prevention & control ; Chickenpox Vaccine ; Child ; Children ; Exanthema ; Herpes zoster ; Herpes Zoster - prevention & control ; Herpesvirus 3, Human - immunology ; Humans ; Immunity ; Leukemia - complications ; Leukemia - immunology ; Pediatrics ; United States ; Vaccination ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Viruses</subject><ispartof>The Journal of infectious diseases, 1992-08, Vol.166 (Supplement-1), p.S63-S68</ispartof><rights>Copyright 1992 The University of Chicago</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-d4baab40228d61ccd764d62e17ff353d1e69fac127c358134a956b9c87ce02813</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30111789$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30111789$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,777,781,800,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1320652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gershon, Anne A.</creatorcontrib><creatorcontrib>LaRussa, Philip</creatorcontrib><creatorcontrib>Hardy, lain</creatorcontrib><creatorcontrib>Steinberg, Sharon</creatorcontrib><creatorcontrib>Silverstein, Saul</creatorcontrib><title>Varicella Vaccine: The American Experience</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-tomoderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV) have developed. Adult vaccinees have a lower degree of protection (70%) than children. Vaccinees who develop breakthrough varicella usually have a modified infection. Another significant advantage of vaccination is that in leukemic children it leads to a lower incidence of zoster than after natural chickenpox. It is possible to differentiate between vaccine-type and wild-type VZV using a combination of polymerase chain reaction and restriction endonuclease digestion. A new assay for antibodies to VZV measured by latex agglutination reveals that 8–10 years after vaccination antibodies are detectable in >90% of leukemic children who have not had breakthrough varicella.</description><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Chickenpox</subject><subject>Chickenpox - prevention & control</subject><subject>Chickenpox Vaccine</subject><subject>Child</subject><subject>Children</subject><subject>Exanthema</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - prevention & control</subject><subject>Herpesvirus 3, Human - immunology</subject><subject>Humans</subject><subject>Immunity</subject><subject>Leukemia - complications</subject><subject>Leukemia - immunology</subject><subject>Pediatrics</subject><subject>United States</subject><subject>Vaccination</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkNtKw0AQQBdRaq1-ghAQfBDS7mST3USfSqlWrBdoreLLstlMMLW5mE2g_r2pKa1PM8yZG4eQC6B9oAEbJFkcJWYAnPdndVGsMMWsktCfcXZAuuAxYXMO7JB0KXUcG_wgOCYnxiwppS7jokM6wBzKPadLrhaqTDSuVspaKK2TDK-t-SdawxSbusqs8bpoMsw0npKjWK0Mnm1jj7zejuejiT19vrsfDae2ZoJXduSGSoVuc9mPOGgdCe5G3EEQccw8FgHyIFYaHKGZ5wNzVeDxMNC-0EidptAjl-3eosy_azSVTBPz92KGeW2kYNRjNNg03rSNusyNKTGWRZmkqvyRQOXGlGxNycaU_G9KNqaa6fPtmTpMMdrPtmr2fGmqvNxhRgFA-EHD7ZYnpsL1jqvyS3LBhCcn7x_y7Yk_vjw4vlywX7voglQ</recordid><startdate>19920801</startdate><enddate>19920801</enddate><creator>Gershon, Anne A.</creator><creator>LaRussa, Philip</creator><creator>Hardy, lain</creator><creator>Steinberg, Sharon</creator><creator>Silverstein, Saul</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920801</creationdate><title>Varicella Vaccine: The American Experience</title><author>Gershon, Anne A. ; LaRussa, Philip ; Hardy, lain ; Steinberg, Sharon ; Silverstein, Saul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-d4baab40228d61ccd764d62e17ff353d1e69fac127c358134a956b9c87ce02813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Chickenpox</topic><topic>Chickenpox - prevention & control</topic><topic>Chickenpox Vaccine</topic><topic>Child</topic><topic>Children</topic><topic>Exanthema</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - prevention & control</topic><topic>Herpesvirus 3, Human - immunology</topic><topic>Humans</topic><topic>Immunity</topic><topic>Leukemia - complications</topic><topic>Leukemia - immunology</topic><topic>Pediatrics</topic><topic>United States</topic><topic>Vaccination</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gershon, Anne A.</creatorcontrib><creatorcontrib>LaRussa, Philip</creatorcontrib><creatorcontrib>Hardy, lain</creatorcontrib><creatorcontrib>Steinberg, Sharon</creatorcontrib><creatorcontrib>Silverstein, Saul</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gershon, Anne A.</au><au>LaRussa, Philip</au><au>Hardy, lain</au><au>Steinberg, Sharon</au><au>Silverstein, Saul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Varicella Vaccine: The American Experience</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1992-08-01</date><risdate>1992</risdate><volume>166</volume><issue>Supplement-1</issue><spage>S63</spage><epage>S68</epage><pages>S63-S68</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-tomoderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV) have developed. Adult vaccinees have a lower degree of protection (70%) than children. Vaccinees who develop breakthrough varicella usually have a modified infection. Another significant advantage of vaccination is that in leukemic children it leads to a lower incidence of zoster than after natural chickenpox. It is possible to differentiate between vaccine-type and wild-type VZV using a combination of polymerase chain reaction and restriction endonuclease digestion. A new assay for antibodies to VZV measured by latex agglutination reveals that 8–10 years after vaccination antibodies are detectable in >90% of leukemic children who have not had breakthrough varicella.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>1320652</pmid><doi>10.1093/infdis/166.Supplement_1.S63</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1992-08, Vol.166 (Supplement-1), p.S63-S68 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73053091 |
| source | MEDLINE; Jstor Complete Legacy |
| subjects | Adult Antibodies Antibodies, Viral - biosynthesis Chickenpox Chickenpox - prevention & control Chickenpox Vaccine Child Children Exanthema Herpes zoster Herpes Zoster - prevention & control Herpesvirus 3, Human - immunology Humans Immunity Leukemia - complications Leukemia - immunology Pediatrics United States Vaccination Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Viral Vaccines - adverse effects Viral Vaccines - immunology Viruses |
| title | Varicella Vaccine: The American Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A59%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Varicella%20Vaccine:%20The%20American%20Experience&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Gershon,%20Anne%20A.&rft.date=1992-08-01&rft.volume=166&rft.issue=Supplement-1&rft.spage=S63&rft.epage=S68&rft.pages=S63-S68&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/166.Supplement_1.S63&rft_dat=%3Cjstor_proqu%3E30111789%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73053091&rft_id=info:pmid/1320652&rft_jstor_id=30111789&rfr_iscdi=true |